<DOC>
	<DOCNO>NCT02532855</DOCNO>
	<brief_summary>The purpose study assess effect addition sitagliptin metformin without sulfonylurea compare addition dapagliflozin metformin without sulfonylurea hemoglobin A1c ( A1C ) 24 week treatment well overall safety tolerability sitagliptin comparison dapagliflozin 24 week treatment . The primary hypothesis change baseline A1C participant treat addition sitagliptin non-inferior compare participant treat addition dapagliflozin 24 week treatment .</brief_summary>
	<brief_title>A Study Assess Addition Sitagliptin Metformin Compared With Addition Dapagliflozin Metformin Participants With Type 2 Diabetes Mellitus ( T2DM ) Mild Renal Impairment Who Have Inadequate Glycemic Control Metformin With Without Sulfonylurea ( MK-0431-838 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion Criteria Have T2DM Screening visit Be metformin monotherapy ≥1500 mg/day alone combination sulfonylurea agent ( dose ≥ 50 % maximum label dose country investigational site ) ≥8 week Is male female reproductive potential ( defined one postmenopausal hysterectomy and/or bilateral oophorectomy , bilateral tubal ligation occlusion least 6 week prior Screening visit ) . If participant female reproductive potential , must agree remain abstinent heterosexual activity agree use ( partner use ) acceptable contraception prevent pregnancy receive blind study drug 14 day last dose blind study drug Has history type 1 diabetes mellitus history ketoacidosis Has history secondary cause diabetes Has know hypersensitivity intolerance dipeptidyl peptidase IV ( DPP4 ) inhibitor sodiumglucose cotransporter 2 ( SGLT2 ) inhibitor Has treat antihyperglycemic agent ( AHA ) metformin participant dual combination therapy , sulfonylurea within 12 week screen Intends initiate weight loss medication study period Has undergone bariatric surgery within 12 month Screening visit Has start weight loss medication medication associate weight change within prior 12 week . Has history myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , heart failure within 3 month Screening visit Has history malignancy ≤5 year prior study , except adequately treat basal cell squamous cell skin cancer situ cervical cancer Has human immunodeficiency virus ( HIV ) Has blood dyscrasia disorder cause hemolysis unstable red blood cell , clinically important hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Has medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Is currently treat hyperthyroidism thyroid replacement therapy stable dose least 6 week prior Screening visit Is likely require treatment ≥14 consecutive day repeat course corticosteroid Is likely require treatment ≥7 consecutive day nonsteroidal antiinflammatory drug Is pregnant breastfeeding , plan conceive study , include 14 day follow last dose blind study drug Is plan undergo hormonal therapy preparation donate egg study , include 14 day follow last dose blind study drug Routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week engages binge drinking Has donate blood blood product within 6 week Screening visit plan donate blood blood product time study</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>